Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRMakoto Maemondo, Toshihiro Nukiwa, Satoshi Morita et al.|New England Journal of Medicine|2010Cited by 5.6k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic ReprogrammingYoichiro Mitsuishi, Hozumi Motohashi, Tatsuhiro Shibata et al.|Cancer Cell|2012Cited by 1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisArata Azuma, Toshihiro Nukiwa, Eiyasu Tsuboi et al.|American Journal of Respiratory and Critical Care Medicine|2005Cited by 953
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Kana Watanabe et al.|The Lancet Oncology|2019Cited by 636
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for ChemotherapyAkira Inoue, Koichi Hagiwara, Kunihiko Kobayashi et al.|Journal of Clinical Oncology|2009Cited by 516